Jim Simons Aptinyx Inc. Transaction History

Renaissance Technologies LLC

  • $56.7 Billion
  • Q2 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
SELL
$0.12 - $0.69 $19,920 - $114,539
-166,000 Reduced 26.85%
452,226 $56,000
Q4 2022

Feb 13, 2023
BUY
$0.23 - $0.34 $17,756 - $26,248
77,200 Added 14.27%
618,226 $176,000
Q3 2022

Nov 14, 2022
SELL
$0.35 - $0.72 $9,760 - $20,079
-27,888 Reduced 4.9%
541,026 $199,000
Q2 2022

Aug 12, 2022
BUY
$0.38 - $2.58 $116,275 - $789,449
305,988 Added 116.38%
568,914 $317,000
Q1 2022

May 13, 2022
SELL
$2.27 - $3.62 $227 - $362
-100 Reduced 0.04%
262,926 $597,000
Q4 2021

Feb 11, 2022
SELL
$2.11 - $3.0 $449,252 - $638,748
-212,916 Reduced 44.74%
263,026 $702,000
Q3 2021

Nov 12, 2021
SELL
$2.21 - $2.89 $314,958 - $411,868
-142,515 Reduced 23.04%
475,942 $1.11 Million
Q2 2021

Aug 13, 2021
SELL
$2.39 - $3.5 $310,080 - $454,093
-129,741 Reduced 17.34%
618,457 $1.75 Million
Q1 2021

May 13, 2021
SELL
$2.86 - $4.33 $577,582 - $874,452
-201,952 Reduced 21.25%
748,198 $2.25 Million
Q4 2020

Feb 10, 2021
BUY
$2.93 - $4.3 $535,709 - $786,194
182,836 Added 23.83%
950,150 $3.29 Million
Q3 2020

Nov 13, 2020
BUY
$3.05 - $4.99 $175,985 - $287,923
57,700 Added 8.13%
767,314 $2.59 Million
Q2 2020

Aug 13, 2020
BUY
$1.99 - $4.4 $379,463 - $839,014
190,685 Added 36.75%
709,614 $2.96 Million
Q1 2020

May 14, 2020
BUY
$1.81 - $5.03 $382,414 - $1.06 Million
211,279 Added 68.68%
518,929 $1.12 Million
Q4 2019

Feb 13, 2020
BUY
$2.84 - $4.25 $623,238 - $932,662
219,450 Added 248.81%
307,650 $1.05 Million
Q3 2019

Nov 13, 2019
BUY
$3.0 - $4.08 $231,600 - $314,976
77,200 Added 701.82%
88,200 $308,000
Q2 2019

Aug 12, 2019
BUY
$2.95 - $4.38 $32,450 - $48,180
11,000 New
11,000 $37,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email